Music and Pharmaceutical Royalty Funds

How it works

A royalty fund buys an existing income stream rather than a business: a share of the royalties a catalogue or a drug already generates. There is no operation to run afterward, no product to manufacture or market, just a contractual right to collect what flows through an existing distribution chain.

Music deals involve two separate copyrights. The sound recording, or master, pays the recording side. The underlying composition pays publishing, which splits further into mechanical, performance and synchronisation income. Publishing income is collected by performing rights organisations such as ASCAP and BMI, by mechanical licensing bodies, and by publishers and administrators, before flowing to whoever owns the acquired share. Catalogues are priced as a multiple of net publisher's share or of recent net income, and the buyer's central judgement is the decay curve: how fast streaming income falls after purchase and where it eventually settles.

Pharmaceutical royalties are typically a percentage of a drug's net sales, originally granted to a university, research institute or inventor, and later sold for a lump sum to a royalty buyer. Synthetic royalties are created rather than bought: a funder gives a developer cash today in exchange for a royalty on future sales, which is closer to a financing than a purchase.

Deals are documented as an assignment of royalty rights with audit provisions, and diligence turns on the contracts, the chain of title, and how reliably the payer reports. Investors reach the asset class through private funds, a small number of listed royalty companies, and retail platforms selling fractional interests in individual catalogues.

What it pays

Music royalty funds distribute as statements arrive from collection societies and administrators, typically quarterly or semi-annually, with a long reporting lag between the stream being played and the money arriving. Pharmaceutical royalty income arrives quarterly from the licensee's sales reports as a percentage of net sales, subject to any tiers, caps or step-downs written into the original agreement.

Music income is driven by streaming volumes and per-stream rates, synchronisation placements in film and advertising, the age and cultural durability of the catalogue, and the statutory rates set through the Copyright Royalty Board process. Pharmaceutical income is driven by prescription volumes, net price after rebates, competition, and the time remaining before loss of exclusivity, at which point the royalty ends.

Both are quoted to investors as a yield on purchase price alongside a total-return target, and both include a return-of-capital component because the stream is finite. A royalty is a wasting asset: copyright terms are long but income decays, and a drug royalty typically ends within a defined and largely knowable period.

Catalogue sales at the end of a fund's life are a second source of return, and the price achieved depends entirely on the multiple buyers are paying at that moment, not on how the catalogue performed while held.

Costs and taxes

Private funds charge management and performance fees, and the diligence and administration on catalogue acquisitions are expensive relative to the size of many deals. Royalty administration fees are also deducted along the chain by collection societies, administrators and sub-publishers before the fund receives anything.

For US federal tax, royalty income received by a fund is generally ordinary income and is reported to investors on a Schedule K-1 for partnerships. Purchased royalty rights are intangible assets that can be amortised, commonly over fifteen years under section 197 when acquired as part of a trade or business, which shelters part of the cash distributed.

Foreign-source royalty income can be subject to withholding at source, with treaty relief and foreign tax credits handled at the fund level. Distributions in excess of taxable income reduce the investor's basis rather than being taxed immediately, which is a normal feature of a wasting-asset structure.

Listed royalty companies distribute as ordinary corporate dividends and report on a 1099, which is a materially simpler tax profile than a partnership K-1.

Liquidity and time commitment

Private royalty funds are closed-end with multi-year lives. Capital returns as the streams pay down or as catalogues are sold at the end, not on demand. Listed royalty companies trade daily and provide the exposure with a market price, market volatility and no lock-up.

Retail fractional-catalogue platforms have operated secondary markets whose depth has varied considerably and cannot be relied on for an exit. Catalogue sales are the main exit route for a private fund, and the achievable price depends on where acquisition multiples sit at that moment rather than on how the catalogue performed.

Effort is low across the category. The timetable is set by royalty statements, which arrive slowly and in arrears, not by the investor's schedule. Access to private funds is generally limited to accredited or institutional investors, while listed vehicles and fractional platforms are open more broadly.

How it goes wrong

Overpaying the multiple is the central risk. Catalogue prices are set by competition among buyers and by the cost of the debt used to fund purchases; when financing costs rose, catalogues bought at peak multiples were written down, and the difficulties at listed music-royalty vehicles made the point publicly. Faster decay than modelled compounds the problem: a catalogue whose streams fall away once a promotional cycle, a film placement or a nostalgia wave ends produces far less than the underwriting assumed.

Chain-of-title problems are specific to catalogues built on decades-old contracts. Buying a share that turns out to be disputed or already assigned is money simply gone. Related to this is black-box income and reporting error: collection societies and administrators pay on data of variable quality, unmatched royalties sit unallocated, and audits recover money slowly if at all.

On the pharmaceutical side, loss of exclusivity ends a royalty almost overnight once generic or biosimilar entry occurs. The date is knowable in advance but the cliff is very steep, and competition, a safety finding or a label restriction can cut a drug's sales long before any patent expires, since the royalty tracks sales rather than the patent itself. Policy risk on drug pricing, including the Medicare price negotiation programme created by the Inflation Reduction Act, changes the net sales figure a royalty is calculated on.

Statutory rate changes and licensing disputes shift music income without anything happening to the songs themselves, since much of the payout is set by regulatory process rather than by negotiation.